Results 171 to 180 of about 1,377,243 (284)

Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets

Annals of Human Genetics, Volume 90, Issue 5, Page 294-302, September 2026.
ABSTRACT Aims There is no proven treatment to prevent the growth or rupture of abdominal aortic aneurysm (AAA). As an aneurysm enlarges over time, the risk of fatal aortic rupture increases. Metformin, a drug usually prescribed to treat Type 2 diabetes, has previously been associated with reduced AAA risk in observational studies. Our aim was to assess
Katie Louise Saxby, Svetlana Stoma, Frank Dudbridge, Nilesh J. Samani, Matthew J. Bown, Christopher P. Nelson   +5 more
wiley   +1 more source

Evaluation of %CV and average glucose derived from pre- and postprandial 6-point glucose measurements for assessing hypoglycemia risk. [PDF]

J Diabetes Investig
Soga R, Torimoto K, Uemura F, Okada Y, Nakayamada S.   +4 more
europepmc   +1 more source

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT Aim Patients with chronic kidney disease (CKD) have an increased cardiovascular risk. Since neutrophils and neutrophil‐borne proteins contribute to cardiovascular disease, we analyzed the neutrophil phenotype in patients with CKD who presented with a spectrum of cardiovascular comorbidities.
Sonja Vondenhoff, Alessandra Antwerpen, Carolina Victoria Cruz Junho, Philipp Martin, Sina Hourtz, Jinmi Zou, Berkan Kurt, Carolin Haas, Susanne Fleig, Corinna Schulte, Jane Lauxen, Martina Wessiepe, Ulrike Späte‐Schulze, Rafael Kramann, Jürgen Floege, Oliver Soehnlein, Joachim Jankowski, Claudia Goettsch, Yvonne Döring, Florian Kahles, Nikolaus Marx, Constance C. F. M. J. Baaten, Heidi Noels   +22 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock, Chantal Mathieu, Joshua Buron Feinberg, Priyanka Rao, Cathrine Scavenius, Alice Y. Y. Cheng   +5 more
wiley   +1 more source

Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study. [PDF]

BMC Endocr Disord
Kiran Z, Fatima N, Baloch AA, Shaikh KUS, Hasan SM, Khan MU.   +5 more
europepmc   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8157-8171, September 2026.
ABSTRACT Objective Soluble receptor for advanced glycation end‐products (sRAGE) and soluble Toll‐like receptor 4 (sTLR4) are circulating pattern recognition receptor isoforms implicated in inflammatory regulation in type 2 diabetes mellitus (T2DM). This study examined the effects of supervised aerobic exercise training (AET) on circulating sRAGE, sTLR4,
Ryan K. Perkins, Corey E. Mazo, James Shadiow, Pallavi Varshney, Edwin R. Miranda, Victoria R. Miranda, Maggie Eisenberg, Jane E. Nakamura, Elif A. Oral, Jacob M. Haus   +9 more
wiley   +1 more source

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities. [PDF]

MedComm (2020)
Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G.   +5 more
europepmc   +1 more source